Evaluation of the Implementation and Effectiveness of IPP-HPV

• Status: Recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the proposed pilot study is to assess the implementation of IPP-HPV immunization at Yale New Haven Hospital (YNHH) and to identify potential barriers to and facilitators of this intervention to optimize its feasibility and effectiveness. It is imperative that innovative interventions be developed to achieve comprehensive utilization of this highly effective vaccine to reduce rates of HPV infection, lower rates of cervical and other HPV associated cancers, and address cancer disparities.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: National Cancer Institute (NCI)
• Treatments: Vaccines

Criteria

Inclusion Criteria:

• Women participating in the IPP-HPV Quality Improvement Program:

• Postpartum YNHH Women's Center and CWHM patients

• ≤ 26 years at time of delivery who deliver at YNHH YSC or SRC

• Have not already received 3 doses of the HPV vaccine at time of delivery

• Fluent in English or Spanish

• Able and willing to provide consent

AND

• Yale New Haven Hospital (YNHH) Women's Center and Center for Women's Health and Midwifery (CWHM) postpartum patients

• ≤ 26 years of age

• Delivered at YNHH York Street Campus (YSC) or Saint Raphael Campus (SRC) in the first year of the IPP-HPV program or in the one year preceding implementation of the program

OR

• YNHH inpatient postpartum nurses or Women's Center outpatient postpartum nurses or inpatient or outpatient obstetric providers affiliated with the Women's Center or Center for Women's Health and Midwifery

• Able and willing to provide consent

Exclusion Criteria:

-